Celebrating life stories...

Memories

 

Memorial created 01-24-2007 by
Wendy Graca
Douglas Owen Nunes
October 28 1950 - January 23 2007

This page has been created by the Nunes Family because we initially came across the virtual memorials website while conducting on-line research regarding brain tumors and related medical treatments. This Memorial site is a link on the Musella Foundation website (www.virtualtrials.com), so for those who have come here seeking the same information we were originally looking for, we'd like to provide as many resources as WE could find in an attempt to help YOU.

THERE HAS BEEN A GROUND-BREAKING NEW PROCEDURE DISCOVERED THAT MAY HELP IN CURING BRAIN CANCER IN OUR NEAR FUTURE.....ALTHOUGH IT'S NOT YET PRACTICED ON HUMANS, IT DOES LEND US HOPE. TO LEARN MORE ABOUT THIS DEVELOPMENT, PLEASE GO TO:

http://www.yale.edu/opa/newsr/08-02-21-02.all.html

Yale Lab Engineers Virus That Can Kill Deadly Brain Tumors

New Haven, Conn. — A laboratory-engineered virus that can find its way through the vascular system and kill deadly brain tumors has been developed by Yale School of Medicine researchers, it was reported this week in the Journal of Neuroscience.

Each year 200,000 people in the United States are diagnosed with a brain tumor, and metastatic tumors and glioblastomas make up a large part of these tumors. There currently is no cure for these types of tumors, and they generally result in death within months.

Anthony van den Pol, professor of neurosurgery at Yale, said current treatments include chemotherapy, radiation, and surgery, which can prolong life for a few months, but generally fail because they don’t eliminate all of the cancer cells.

To test their tumor-targeting virus, van den Pol and his team transplanted tumor tissue from human or mouse brains into the brains of mice. They then inoculated the mice with a lab-created vesicular stomatitis virus, a replicating virus distantly related to the rabies virus.

“Three days after inoculation, the tumors were completely or almost completely infected with the virus and the tumor cells were dying or dead,” van den Pol said. “We were able to target different types of cancer cells. Within the same time frame, normal mouse brain cells or normal human brain cells transplanted into mice were spared. This underlines the virus’ potential therapeutic value against multiple types of brain cancers.”

The team also tested targeting brain tumors with the virus through the olfactory nerve and found it led to complete infection of the tumor. After infection, the tumor cells disappeared from the olfactory bulb, van den Pol said.

Co-authors include lead author Koray Özduman, Guido Wollmann, and Joseph Piepmeier.

Journal of Neuroscience: February 20, 2008

 

The following is a list of websites that give some basic and in-depth information regarding brain cancer and treaments:

www.virtualtrials.com www.btan.org www.braintumor.org www.braintrust.org www.tbts.org www.btsurvivor.com www.brainhospice.com www.clinicaltrials.gov/ct/gui/show/NCT00285324?order=6 http://hope.abta.org http://www.ozbraintumour.org/journey.htm http://en.wikipedia.org/wiki/Glioblastoma_multiforme http://www.emedicinehealth.com/brain_cancer/article_em.htm http://www.medicinenet.com/brain_tumor/article.htm http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=3 http://www.isracast.com/articles/article.aspx?ID=15 http://www.cancer.gov/clinicaltrials/results/glioblastoma0604 http://bethesdatrials.cancer.gov/investigator-profiles/fine/default.asp http://cebp.aacrjournals.org/cgi/content/abstract/4/3/275 http://cebp.aacrjournals.org/cgi/reprint/4/3/275 (this will provide a pdf version of same article above)

 

The following is a list of websites for several treatment centers located in various areas of the country: http://www.bidmc.harvard.edu/default.asp?node_id=6 http://radonc.duke.edu/modules/radoncfindphysician/index.php?id=1 http://www.umm.edu/altmed/ConsConditions/CancerBraincc.html http://www.mayoclinic.com/health/brain-tumor/DS00281 http://www.mdanderson.org/diseases/braincancer/ http://www.stjude.org/brain-tumors?source=overture&kw=brain+tumor Different types of available treatment regimens: chemotherapy (CCNU or BCNU) radiotherapy surgical resection radiosurgery viral therapy topical mineral spa protocol enzyme & vitamin therapy live cell therapy monoclonal antibody procedure

 

New Agents becoming available: Avastin (Bevacizamab) -manufactured by Genentech STI-571 (Gleevec) Iressa (Gefitinib or ZD 1839) oral Erlotinib (Tarceva OSI-774) Rapamycin (ramapune, sirolimus) Tamoxifen (used previously in breast cancer) Herceptin (manufactured by Genentech) Bortezomib (Velcade) see http://en.wikipedia.org/wiki/Bortezomib or http://www.cancer.gov/clinicaltrials/results/bortezomib0604

 

Supplements with efficiacy: Accutane (by prescription only) Thalidomide (by prescription only) Celebrex or Vioxx (by prescription only) Chlorimipramine (by prescription only) rosiglitazone (Avandia)-used to treat diabetes pioglitazone (Actos)-used to treat diabetes GLA (gamma lineolic acid) & fish oil PSK (polysaccharide krestin-Coriolus Versicolor)-used to treat cancer in Japan Melatonin Vitamin D

 

Supplements with potential efficiacy not yet clinically tested: Genistein Selenium Green Tea Quercetin Curcumin Silibinin Bromelain Lycopene Boswellic Acid Broccoli Sprouts Ellagic Acid Berberine Resveratrol tienhsien.com tahitian noni juice (www.libertyzone.com/hz-brain-cancer-T1.html)

 

For some of the supplements listed above: www.lef.org Another site where you can find suggestions on the best nutrition for a brain cancer patient and ways to purchase alternative herbs and supplements: www.nutritional-solultions.net

 
Vaccine being administered by doctor.
 

JULY 9, 2007 Copied From: http://news.yahoo.com/s/afp/20070709/hl_afp/britainswitzerlandus PIONEERING TREATMENT FOR BRAIN CANCER GETS SWISS APPROVAL An experimental treatment for brain cancer has won approval for commercial use in Switzerland, its London-listed US maker, Northwest Biotherapeutics, Inc., announced on Monday. DCVax-Brain will be available to patients in selected hospitals and medical centres in Switzerland before the end of September, the first time a treatment of this kind has been given market authorisation, it said in a statement. "We are delighted to be the first company to reach the market with a personalized therapeutic vaccine for brain cancers, which carry a very bleak prognosis for patients," said Alton Boynton, president and chief executive of Northwest Biotherapeutics. DCVax-Brain is designed to treat cancer by priming the patient's immune system to attack cancer cells. The patient's own master immune cells, known as dendritic cells, are taken from the bloodstream while they are still at an immature stage. These precursor cells are then matured in a lab dish while being exposed to biomarkers from the patient's own tumour, thus helping them to identify the cancer foe. Once they reach adult stage, the cells are injected back into the patient's body. DCVax-Brain is currently in the second phase of the typical three-phase process of testing a new drug for safety and efficacy before it is licenced by the US Food and Drug Administration (FDA) and other medical watchdogs. It is being tested on 141 patients in the United States with glioblastoma multiforme, an especially aggressive form of cancer. The Swiss Agency for Therapeutic Products, known as Swissmedic, decided to approve the company's request for a commercial licence on the basis of ongoing clinical data, Northwest Biotherapeutics said. Brain cancers are among the swiftest of lethal cancers. Patients with the disease have on average only 14.6 months to live after diagnosis. Data from the trial showed that patients treated with DCVax-Brain more than doubled this survival time compared to counterparts who did not get the drug, meaning that they had lived to more than 33 months or were still alive at the end of that phase of the trial, the statement said. In addition, unlike chemotherapy, the drug "does not cause any debilitating side effects," it said. In addition, the treatment was found to delay recurrence of the disease by nearly three fold, from 6.9 months to 18.1 months among patients who were newly diagnosed. Boynton said "Switzerland is an attractive place to begin commercialization, due to its highly respected regulatory oversight, and its growing experience with cellular therapies." He added: "Switzerland is also increasingly noted for medical tourism, and is easily accessible for many medical tourists

 

for an incredibly inspiring and encouraging story of survival, go to: http://virtualtrials.com/pdf/williams2006.pdf Information is being updated and added to this website on a regular basis. Please check back for more information frequently. If you have pertinent information regarding brain cancer and/or treatments that you feel should be posted on this page, please contact us at: DNMemorialFund@yahoo.com. Or, if you see a discrepancy let us know. We'll be glad to add it or make any corrections. Thanks!

 

Please sign the guestbook for Douglas by clicking here

This page has been visited 18895 times

 

Honor, cherish and share your loved one's story.

 

About VM    ::    FAQ    ::    Create    ::    Terms of Use    ::    Privacy Policy    ::    Resources    ::    Contact
Copyright (1996-2015) Virtual Memorials Inc. All rights reserved.